Scinai Immunotherapeutics (SCNI) Accounts Payables (2015 - 2026)

Scinai Immunotherapeutics has disclosed Accounts Payables across 12 years of filings, most recently posting $844000.0 for Q2 2026.

• In Q2 2026, Accounts Payables rose 28.07% year-over-year to $844000.0; the TTM figure through Jun 2026 stood at $844000.0 (up 28.07% YoY), while the FY2025 annual figure was $407000.0, up 8.24% from the prior year.
• Accounts Payables came in at $844000.0 for Q2 2026 at Scinai Immunotherapeutics, up from $779000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.3 million in Q1 2023 to a low of $297000.0 in Q3 2022.
• Average Accounts Payables over 5 years is $700687.5, with a median of $658500.0 recorded in 2024.
• Year-over-year, Accounts Payables plunged 77.69% in 2022 and surged 83.84% in 2023.
• Over 5 years, Accounts Payables stood at $716000.0 in 2022, then dropped by 25.28% to $535000.0 in 2023, then declined by 29.72% to $376000.0 in 2024, then climbed by 8.24% to $407000.0 in 2025, then surged by 107.37% to $844000.0 in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $844000.0 in Q2 2026, $779000.0 in Q1 2026, and $407000.0 in Q4 2025.